The deal includes a value of $270 million, with certain amounts held in escrow for a period dependent on uninterrupted business operation. Tokyo-based Olympus expects to complete the deal by the end of the second quarter of 2026.
BioProtect develops implant technologies designed to improve prostate cancer care. It designed its flagship Balloon Spacer device to provide consistent spacing between the prostate and other critical structures. This protects healthy tissues during prostate cancer radiation therapies. After treatment, the implant naturally biodegrades.
The company introduced the Balloon Spacer commercially in 2023. Since then, it reports more than 11,000 procedures worldwide. The company says the device demonstrates preserved gastrointestinal, urinary and sexual functions for patients.
Olympus said its acquisition aligns with its strategic pillar labeled “Innovation-driven Growth.” It hopes to target an unmet need in prostate cancer, expanding its portfolio in adjacent therapeutic areas related to endoscopy. That includes gastrointestinal and urological fields, helping to enhance its value proposition across the care pathway. Olympus CEO Bob White outlined some of the company’s future plans in an interview with MassDevice in October 2025.
“We are pleased to welcome BioProtect to Olympus,” said Seiji Kuramoto, executive officer and head of Surgical and Interventional Solutions at Olympus. “BioProtect brings a highly differentiated solution to prostate cancer care, with a compelling clinical value proposition and early commercial success. By combining BioProtect’s strengths with Olympus’ global reach and relationships with healthcare professionals, we believe we can expand access to solutions that support better patient outcomes and help clinicians to advance the treatment of prostate cancer.”
